Article

Archer Materials is pursuing a scalable approach to quantum technology with its 12CQ project, targeting a carbon-based qubit demonstration in 2026. The company focuses on manufacturability and integration with existing semiconductor systems, aiming to lower capital requirements and accelerate time to market.

Additionally, Archer is developing a Biochip for monitoring blood potassium levels, with a prototype expected in 2026. Collaborations with CSIRO and IMEC support its efforts in quantum computing and biosensing. Archer remains debt-free with $10.3 million in cash, positioning itself for continued innovation in both quantum and medical diagnostics.